Related Experiment Video
Updated: Aug 9, 2025
05:10
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
9.7K
In Vitro Drug Repurposing: Focus on Vasodilators.
Eduarda Ribeiro1,2,3, Bárbara Costa1,2, Francisco Vasques-Nóvoa4,5
1OncoPharma Research Group, Center for Health Technology and Services Research (CINTESIS), Rua Doutor Plácido da Costa, 4200-450 Porto, Portugal.
Cells
|February 25, 2023
Summary
Drug repurposing offers a faster path to new cancer treatments. Vasodilators show promise in targeting cancer cells and improving chemotherapy delivery, warranting further research for therapeutic use.
Area of Science:
- Oncology
- Pharmacology
Background:
- Drug repurposing accelerates the discovery of new therapeutic uses for existing medications.
- Vasodilators, known for relaxing blood vessels, exhibit potential anticancer properties.
Purpose of the Study:
- To explore the molecular mechanisms of vasodilators in cancer cell lines.
- To review the current research on repurposing vasodilators as a cancer treatment strategy.
Main Methods:
- Literature review of preclinical and clinical studies on vasodilators in cancer.
- Analysis of molecular mechanisms underlying vasodilator effects on cancer cells.
Main Results:
- Vasodilators increase blood flow to tumors, enhancing chemotherapy delivery.
- Evidence suggests vasodilators possess antiproliferative and proapoptotic effects on cancer cells.
Conclusions:
- Vasodilators represent a promising avenue for drug repurposing in oncology.
- Further research is essential to elucidate mechanisms and optimize vasodilator-based cancer therapies.
Related Concept Videos
01:23Antihypertensive Drugs: Vasodilators
593
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
593
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
213
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
213
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
479
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
479
01:22Heart Failure Drugs: β-Blockers
411
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
411
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
238
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
238
01:16Antianginal Drugs: Nitrates and β-Blockers
675
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
675